Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100517
Muhammad Hassan Raza , Eiraj Khan , Alexis M Desjarlais , Salman Fazal
Introduction and Importance
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (pH-positive ALL) in Jehovah’s Witness (JW) using chemotherapy agents, opens an ethically and morally challenging paradigm instead of their religious practices.
Case Presentation
We present a case of pH-positive B cell ALL in a Jehovah's Witness patient who refused the transfusion of blood as a part of their treatment regimen. We intended to treat this patient using a new “chemotherapy-free” approach and achieved Minimal Residual Disease (MRD) negative state with durable outcomes for the next three years.
Clinical Discussion
With “chemotherapy-free” regimen, we achieved complete molecular remission without any significant side effects in our patient.
Conclusion
Chemo-free approach is a promising opportunity to treat Jehovah’s witnesses with pH-positive B cell ALL as the haemoglobin and platelets remained above transfusion thresholds. However, further research is required to fully understand and implement this approach. Future clinical trials should consider including this unique patient population to better understand their needs and improve outcomes.
{"title":"Management of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in a Jehovah’s Witness using chemotherapy free regimen: A case report and review of literature","authors":"Muhammad Hassan Raza , Eiraj Khan , Alexis M Desjarlais , Salman Fazal","doi":"10.1016/j.lrr.2025.100517","DOIUrl":"10.1016/j.lrr.2025.100517","url":null,"abstract":"<div><h3>Introduction and Importance</h3><div>Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (pH-positive ALL) in Jehovah’s Witness (JW) using chemotherapy agents, opens an ethically and morally challenging paradigm instead of their religious practices.</div></div><div><h3>Case Presentation</h3><div>We present a case of pH-positive B cell ALL in a Jehovah's Witness patient who refused the transfusion of blood as a part of their treatment regimen. We intended to treat this patient using a new “chemotherapy-free” approach and achieved Minimal Residual Disease (MRD) negative state with durable outcomes for the next three years.</div></div><div><h3>Clinical Discussion</h3><div>With “chemotherapy-free” regimen, we achieved complete molecular remission without any significant side effects in our patient.</div></div><div><h3>Conclusion</h3><div>Chemo-free approach is a promising opportunity to treat Jehovah’s witnesses with pH-positive B cell ALL as the haemoglobin and platelets remained above transfusion thresholds. However, further research is required to fully understand and implement this approach. Future clinical trials should consider including this unique patient population to better understand their needs and improve outcomes.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100517"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100520
Bhaumik Shah , Mitra Abdollahi-Neisani , Pegah Taheri , Asya Varshavsky , Reza Nejati , Nicholas Mackrides
The WHO and ICC classifications lack standardized terminology to define the disease phase of chronic myeloproliferative neoplasms in extramedullary sites, particularly lymph nodes, when infiltrates resemble extramedullary hematopoiesis (EH). We report a lymph node case of extramedullary chronic myelomonocytic leukemia (CMML) in blast phase mimicking EH. Comprehensive genomic profiling, using chromosomal microarray and NGS-based sequencing, identified copy neutral loss of heterozygosity (cn-LOH), previously unreported in extramedullary CMML. We discuss challenges in determining the CMML disease phase in lymph nodes and review the literature to underscore the need for consensus terminology for cases not meeting myeloid sarcoma criteria.
{"title":"Diagnostic and taxonomic challenges in chronic myelomonocytic leukemia with lymph node involvement: A case report and mini-review","authors":"Bhaumik Shah , Mitra Abdollahi-Neisani , Pegah Taheri , Asya Varshavsky , Reza Nejati , Nicholas Mackrides","doi":"10.1016/j.lrr.2025.100520","DOIUrl":"10.1016/j.lrr.2025.100520","url":null,"abstract":"<div><div>The WHO and ICC classifications lack standardized terminology to define the disease phase of chronic myeloproliferative neoplasms in extramedullary sites, particularly lymph nodes, when infiltrates resemble extramedullary hematopoiesis (EH). We report a lymph node case of extramedullary chronic myelomonocytic leukemia (CMML) in blast phase mimicking EH. Comprehensive genomic profiling, using chromosomal microarray and NGS-based sequencing, identified copy neutral loss of heterozygosity (cn-LOH), previously unreported in extramedullary CMML. We discuss challenges in determining the CMML disease phase in lymph nodes and review the literature to underscore the need for consensus terminology for cases not meeting myeloid sarcoma criteria.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100520"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We aimed to analyse the incidence of BCR::ABL1 kinase domain mutations in patients newly diagnosed with or undergoing treatment for chronic myeloid leukemia (CML) in Côte d’Ivoire, as well as to evaluate the predictive factors associated with treatment outcomes.
Methods
We evaluated 42 patients with suboptimal molecular response who underwent BCR::ABL1 kinase domain mutation screening. Sequencing was performed in collaboration with the Fred Hutchinson Cancer Research Center, Seattle, USA.
Results
Among the 42 patients, 16 (38.1%) were found to have known BCR::ABL1 point mutations. A total of nine distinct mutations were identified, with T315I being the most common (5). Three patients harbored compound mutations: one had T315I + M244V, another had G250E + E459K, and the third had H396P + E459K. The 5-year overall survival (OS) rate was significantly lower in patients with BCR::ABL1 mutations (85%; 95 % CI: 51.0%–96.1%) compared to those without mutations (100%). However, there was no statistically significant difference in OS between patients with T315I mutations (83.3 %; 95 % CI: 27.4%–97.5%) and those without T315I (83.3%; 95% CI: 5.9%–98.8%). Being in the chronic phase of the disease and having a low-risk ELTS score were identified as protective factors against the development of mutations.
Conclusion
Our findings support the recommendation for BCR::ABL1 mutation screening in CML patients with an inadequate initial response or evidence of loss of response. Screening is also advised at progression to the accelerated or blast phase, and in patients with high-risk ELTS scores, and mutation profiles may serve as important prognostic indicators.
{"title":"BCR::ABL1 kinase domain mutations and their predictive value for treatment outcomes in patients with chronic myeloid leukemia treated with first-line imatinib in a low-income setting: Experience from Côte d’Ivoire","authors":"Kouassi Gustave Koffi , Sara Akou Bognini , Dohoma Alexis Silué , Ismael Kamara , Ines Kouakou , Ruth Dieket , Emeraude N’dhatz , Boidy Kouakou , Danho Clotaire Nanho , Yannick Kouassi , David Tea Okou","doi":"10.1016/j.lrr.2025.100544","DOIUrl":"10.1016/j.lrr.2025.100544","url":null,"abstract":"<div><h3>Background</h3><div>We aimed to analyse the incidence of BCR::ABL1 kinase domain mutations in patients newly diagnosed with or undergoing treatment for chronic myeloid leukemia (CML) in Côte d’Ivoire, as well as to evaluate the predictive factors associated with treatment outcomes.</div></div><div><h3>Methods</h3><div>We evaluated 42 patients with suboptimal molecular response who underwent BCR::ABL1 kinase domain mutation screening. Sequencing was performed in collaboration with the Fred Hutchinson Cancer Research Center, Seattle, USA.</div></div><div><h3>Results</h3><div>Among the 42 patients, 16 (38.1%) were found to have known BCR::ABL1 point mutations. A total of nine distinct mutations were identified, with T315I being the most common (5). Three patients harbored compound mutations: one had T315I + M244V, another had G250E + E459K, and the third had H396P + E459K. The 5-year overall survival (OS) rate was significantly lower in patients with BCR::ABL1 mutations (85%; 95 % CI: 51.0%–96.1%) compared to those without mutations (100%). However, there was no statistically significant difference in OS between patients with T315I mutations (83.3 %; 95 % CI: 27.4%–97.5%) and those without T315I (83.3%; 95% CI: 5.9%–98.8%). Being in the chronic phase of the disease and having a low-risk ELTS score were identified as protective factors against the development of mutations.</div></div><div><h3>Conclusion</h3><div>Our findings support the recommendation for BCR::ABL1 mutation screening in CML patients with an inadequate initial response or evidence of loss of response. Screening is also advised at progression to the accelerated or blast phase, and in patients with high-risk ELTS scores, and mutation profiles may serve as important prognostic indicators.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100544"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145048325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100543
Eman Almatar, Sondus Alsharidah, Omnia A. Hashem
Children with Down syndrome (DS) have a 10–20-fold increased risk of acute lymphoblastic leukemia (ALL) and heightened chemotherapy toxicity. Blinatumomab, a bispecific CD19 × CD3 T-cell engager, offers targeted immunotherapy with reduced myelotoxicity. We describe a 9-year-old girl with DS diagnosed with B-cell precursor ALL in early 2021 who relapsed during maintenance in September 2023. After reinduction, she received two 28-day blinatumomab cycles: the first resulted in <5 % blasts and undetectable minimal residual disease (MRD), and the second was well tolerated. She remains in remission pending allogeneic hematopoietic stem cell transplantation, highlighting blinatumomab’s efficacy and safety as a bridge to transplantation.
{"title":"Management of relapsed acute lymphoblastic leukemia in a patient with down syndrome: A case report","authors":"Eman Almatar, Sondus Alsharidah, Omnia A. Hashem","doi":"10.1016/j.lrr.2025.100543","DOIUrl":"10.1016/j.lrr.2025.100543","url":null,"abstract":"<div><div>Children with Down syndrome (DS) have a 10–20-fold increased risk of acute lymphoblastic leukemia (ALL) and heightened chemotherapy toxicity. Blinatumomab, a bispecific CD19 × CD3 T-cell engager, offers targeted immunotherapy with reduced myelotoxicity. We describe a 9-year-old girl with DS diagnosed with B-cell precursor ALL in early 2021 who relapsed during maintenance in September 2023. After reinduction, she received two 28-day blinatumomab cycles: the first resulted in <5 % blasts and undetectable minimal residual disease (MRD), and the second was well tolerated. She remains in remission pending allogeneic hematopoietic stem cell transplantation, highlighting blinatumomab’s efficacy and safety as a bridge to transplantation.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100543"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Isolated bone marrow gamma/delta T-cell lymphoma: A difficult case to classify according to the current WHO classification of lymphoid malignancies","authors":"Hideto Hyuuga , Naoki Oishi , Takuma Kumagai , Minori Matuura , Ayato Nakadate , Yuma Sakamoto , Jun Suzuki , Megumi Suzuki , Megumi Koshiisi , Ichiro Kawashima , Takeo Yamamoto , Kei Nakajima , Masaru Tanaka , Tetuso Kondo , Keita Kirito","doi":"10.1016/j.lrr.2025.100539","DOIUrl":"10.1016/j.lrr.2025.100539","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100539"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144852637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100541
Nathan M. Krah , Rasmus Hoeg , Paul J. Shami , Shannon E. Elf , Lauren E. Lee , Naveen Pemmaraju , Ami B. Patel
BPDCN is an aggressive myeloid malignancy characterized by unique expression of CD123, CD4, CD56, CD303, CD304, TCL1 and TCF4. The development of tagraxofusp, a CD123-directed cytotoxin, has revolutionized BPDCN treatment, especially for patients unfit for chemotherapy. While most patients respond to frontline tagraxofusp, there are challenges associated with treatment. In this case series, we describe our institutional experience treating BPDCN both pre- and post-tagraxofusp approval. We summarize six cases, the majority of which occurred in elderly patients, and highlight unique challenges of treating BPDCN at a center that serves a large rural/frontier area with variable access to specialty care.
{"title":"Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base","authors":"Nathan M. Krah , Rasmus Hoeg , Paul J. Shami , Shannon E. Elf , Lauren E. Lee , Naveen Pemmaraju , Ami B. Patel","doi":"10.1016/j.lrr.2025.100541","DOIUrl":"10.1016/j.lrr.2025.100541","url":null,"abstract":"<div><div>BPDCN is an aggressive myeloid malignancy characterized by unique expression of CD123, CD4, CD56, CD303, CD304, TCL1 and TCF4. The development of tagraxofusp, a CD123-directed cytotoxin, has revolutionized BPDCN treatment, especially for patients unfit for chemotherapy. While most patients respond to frontline tagraxofusp, there are challenges associated with treatment. In this case series, we describe our institutional experience treating BPDCN both pre- and post-tagraxofusp approval. We summarize six cases, the majority of which occurred in elderly patients, and highlight unique challenges of treating BPDCN at a center that serves a large rural/frontier area with variable access to specialty care.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100541"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100549
Maha Bourusly , Mohammad Adil Obaid , Nashwa Farag , Mona Bourhama , Sundos Alsharidah , Eman Almatar
Pediatric chronic myeloid leukemia is rare and differs from adult disease. We retrospectively reviewed 12 children (median age 8.4 years, six males) treated with imatinib (340 mg/m²/day) from 2010 to 2020; dasatinib was used for intolerance. All presented with leukocytosis (median WBC, 358 × 109/L) and splenomegaly. Imatinib achieved complete hematologic response in 92% by 3 months and 100% by 6 months; major molecular response was observed in all evaluable cases at 12 months. Three who lost response switched to dasatinib and maintained remission; two attained treatment-free remission. TKIs are effective; prospective studies should optimize risk stratification and discontinuation.
{"title":"Pediatric chronic myeloid leukemia: A decade of clinical experience at the NBK specialized hospital for children","authors":"Maha Bourusly , Mohammad Adil Obaid , Nashwa Farag , Mona Bourhama , Sundos Alsharidah , Eman Almatar","doi":"10.1016/j.lrr.2025.100549","DOIUrl":"10.1016/j.lrr.2025.100549","url":null,"abstract":"<div><div>Pediatric chronic myeloid leukemia is rare and differs from adult disease. We retrospectively reviewed 12 children (median age 8.4 years, six males) treated with imatinib (340 mg/m²/day) from 2010 to 2020; dasatinib was used for intolerance. All presented with leukocytosis (median WBC, 358 × 10<sup>9</sup>/L) and splenomegaly. Imatinib achieved complete hematologic response in 92% by 3 months and 100% by 6 months; major molecular response was observed in all evaluable cases at 12 months. Three who lost response switched to dasatinib and maintained remission; two attained treatment-free remission. TKIs are effective; prospective studies should optimize risk stratification and discontinuation.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100549"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145320235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100499
E. Amabile, F. Fazio, M. Martelli, M.T. Petrucci
{"title":"Corrigendum to “First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report” [Leukemia Research Reports (2024) Volume 22, 100491]","authors":"E. Amabile, F. Fazio, M. Martelli, M.T. Petrucci","doi":"10.1016/j.lrr.2025.100499","DOIUrl":"10.1016/j.lrr.2025.100499","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100499"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144298687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100526
Shihab Ahmed Ibrahim Ahmed, Amr Suliman AlHanbali
Asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL) and its variant, T-cell lymphoblastic lymphoma (T-LBL), particularly in adolescents and young adults (AYA). However, its use is associated with a significant risk of thrombotic complications due to its profound effects on coagulation pathways. We report a catastrophic case of asparaginase-induced cerebral and systemic thrombosis in a previously healthy 20-year-old female with T-LBL. Despite prophylactic anticoagulation, the patient developed extensive cerebral venous sinus thrombosis, deep vein thrombosis, and pulmonary embolism, necessitating mechanical thrombectomy, Argatroban therapy, and long-term anticoagulation. This case underscores the multifactorial pathophysiology of asparaginase-associated thrombosis and highlights the need for individualized risk assessment, vigilant monitoring, and dynamic anticoagulation strategies. A comprehensive literature review is provided to contextualize the epidemiology, mechanisms, risk factors, prevention, and management of this life-threatening complication, with practical recommendations for optimizing care in high-risk patients.
{"title":"Catastrophic asparaginase-induced cerebral and systemic thrombosis in a young female with T-cell lymphoblastic lymphoma: A case report & literature review","authors":"Shihab Ahmed Ibrahim Ahmed, Amr Suliman AlHanbali","doi":"10.1016/j.lrr.2025.100526","DOIUrl":"10.1016/j.lrr.2025.100526","url":null,"abstract":"<div><div>Asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL) and its variant, T-cell lymphoblastic lymphoma (T-LBL), particularly in adolescents and young adults (AYA). However, its use is associated with a significant risk of thrombotic complications due to its profound effects on coagulation pathways. We report a catastrophic case of asparaginase-induced cerebral and systemic thrombosis in a previously healthy 20-year-old female with T-LBL. Despite prophylactic anticoagulation, the patient developed extensive cerebral venous sinus thrombosis, deep vein thrombosis, and pulmonary embolism, necessitating mechanical thrombectomy, Argatroban therapy, and long-term anticoagulation. This case underscores the multifactorial pathophysiology of asparaginase-associated thrombosis and highlights the need for individualized risk assessment, vigilant monitoring, and dynamic anticoagulation strategies. A comprehensive literature review is provided to contextualize the epidemiology, mechanisms, risk factors, prevention, and management of this life-threatening complication, with practical recommendations for optimizing care in high-risk patients.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100526"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144623831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100540
Peng fei Tao, Jincheng Lou, Xicheng Wang
Objective
Acquired Immunodeficiency Syndrome (AIDS)-related lymphoma has diverse clinical manifestations, and its diagnosis is often challenging. Misdiagnosis can delay treatment and affect patient prognosis. We assessed the clinical data of eight patients with atypical clinical manifestations of AIDS-related lymphoma, to enhance physicians' understanding of these patients, and reduce the potential for misdiagnosis.
Methods
A retrospective analysis was conducted on eight patients with atypical manifestations of AIDS-related lymphoma admitted to the Department of Infectious Diseases of Yunnan Provincial Hospital between May 2017 and May 2023. They were initially misdiagnosed with opportunistic infections, and were later diagnosed with lymphoma.
Results
The patients comprised five males and three females. Cluster of Differentiation 4 (CD4) counts were lower than 200/μl for all patients, and inflammatory marker levels were elevated to varying degrees. Four patients had recurrent fever, one had bleeding, one had pulmonary infection, one had long-term diarrhoea, and one had visual impairment as the primary symptoms. Six patients were diagnosed through bone marrow cytology and biopsy, one through colonoscopy and pathological biopsy, and one through computed tomography-guided percutaneous lung biopsy. All patients had extranodal involvement, including one case in the intestine, one in the lung, and six in the bone marrow. All patients were at lymphoma stage IV, with four in Group A and four in group B.
Conclusion
In patients with AIDS, particularly those with low CD4 counts and unexplained fever, atypical lymphoma should be considered, and tissue biopsy should be performed to further confirm the diagnosis.
{"title":"Analysis of atypical clinical manifestations in eight patients with AIDS complicated by lymphoma","authors":"Peng fei Tao, Jincheng Lou, Xicheng Wang","doi":"10.1016/j.lrr.2025.100540","DOIUrl":"10.1016/j.lrr.2025.100540","url":null,"abstract":"<div><h3>Objective</h3><div>Acquired Immunodeficiency Syndrome (AIDS)-related lymphoma has diverse clinical manifestations, and its diagnosis is often challenging. Misdiagnosis can delay treatment and affect patient prognosis. We assessed the clinical data of eight patients with atypical clinical manifestations of AIDS-related lymphoma, to enhance physicians' understanding of these patients, and reduce the potential for misdiagnosis.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on eight patients with atypical manifestations of AIDS-related lymphoma admitted to the Department of Infectious Diseases of Yunnan Provincial Hospital between May 2017 and May 2023. They were initially misdiagnosed with opportunistic infections, and were later diagnosed with lymphoma.</div></div><div><h3>Results</h3><div>The patients comprised five males and three females. Cluster of Differentiation 4 (CD<sub>4</sub>) counts were lower than 200/μl for all patients, and inflammatory marker levels were elevated to varying degrees. Four patients had recurrent fever, one had bleeding, one had pulmonary infection, one had long-term diarrhoea, and one had visual impairment as the primary symptoms. Six patients were diagnosed through bone marrow cytology and biopsy, one through colonoscopy and pathological biopsy, and one through computed tomography-guided percutaneous lung biopsy. All patients had extranodal involvement, including one case in the intestine, one in the lung, and six in the bone marrow. All patients were at lymphoma stage IV, with four in Group A and four in group B.</div></div><div><h3>Conclusion</h3><div>In patients with AIDS, particularly those with low CD4 counts and unexplained fever, atypical lymphoma should be considered, and tissue biopsy should be performed to further confirm the diagnosis.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100540"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144914017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号